Among those, CDKN1B resulted significantly mutated in both ER-positive and -negative primary tumors, but not in metastatic/recurrent BC samples, overall confirming the pathological relevance of CDKN1B in BC and putting a particular accent on its involvement more during early steps of tumor initiation rather than during cancer progression (60). This evidence concerns the gene CDKN1B and breast cancer.